Moderna laboratories reported on the progress of the clinical trials of the vaccine once morest the Human Immunodeficiency Virus (HIV) and announced that the first dose of the biological messenger RNA (mRNA) that this company prepares to combat the disease has already been applied.
Amid the drugmaker’s announcement, Stephen Hoge, MD, chairman of Moderna, recalled the struggles the world has had regarding the fight once morest HIV and stressed that they were hopeful that mRNA would be the answer, as it would be offering a new approach to combating the virus.
“Development of a vaccine regimen that induces sustained protective levels of HIV-neutralizing antibodies in humans has been elusive. At Moderna, we believe that mRNA offers an opportunity to take a new approach to this challenge,” said Hoge.
And I add, “this study is another step in our fight once morest HIV, as well as other latent viruses, such as our recently launched studies on CMV and EBV.” referring to the importance of this clinical trial and the vaccine being tested for the fight once morest disease that more than 37.7 million people have, according to figures from the World Health Organization (WHO), of which 1.2 million patients would be concentrated in the United States.
The first dose given would be the key to the launch of the second trial of the vaccine, according to Hoge, The strategy that this company would be using is the use of multiple native HIV trimers encoded in mRNA, with the aim of taking advantage of the platform that was already developed with this type of RNA and, thus, affirms that they would be able to discover faster a vaccine that protect once morest disease.
“It is gratifying to see that experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field. We are optimistic that this study will pave the way for continued approaches to using mRNA in HIV.”, assured Dr. Larry Corey, principal investigator of the HIV Vaccine Trials Network (HVTN) Leadership Operations Center, emphasizing the importance of the advances made in the midst of research to combat covid-19. 19, in other aspects of science.
The company recalled that it is currently working on two preventive vaccine strategies once morest the virus, which would be focused on the germ line and immunological, as well as other actions related to HIV antigen tests.
“In addition to this mRNA-1574 HIV trimer mRNA vaccine trial, Moderna is partnering on HIV mRNA-1644 and mRNA-1644v2-Core vaccine antigen testing, being evaluated in a Phase 1 trial. I sponsored by IAVI and supported by the Bill and Melinda Gates Foundation”, they continued explaining, in addition to emphasizing that these advances would be in part due to the support of the Gates family, who have shown themselves in different scenarios, defending and affirming the need for strengthen scientific research.
